PRODUCTS
Comprehensive Genomic Profiling (CGP) uses next-generation sequencing (NGS) to evaluate multiple clinically relevant biomarkers within a solid tumor. It provides detailed genomic resolution, enabling the detection of single nucleotide variants (SNVs), insertions and deletions (indels), copy number variations (CNVs), select gene fusions, and key cancer genomic signatures such as tumor mutational burden (TMB) and microsatellite instability (MSI).
By consolidating this information into a single assay, CGP offers a complete view of a tumor’s molecular profile, reducing the need for multiple tumor-specific panels or separate testing methods.
Combines samples from all tumor types into a single test platform, enabling efficient batching and streamlined workflow.
Focuses on clinically and research-relevant information, supporting treatment decisions and drug development strategies.
More efficient and economical than whole-exome sequencing (WES) for oncology, lowering resource use while maintaining comprehensive genomic coverage.
Clinical Genomics Manager - ANZ & Country Manager - NZ
Enable improved Tx Selection and enhanced Clinical Research
Fixed Panel + Customisation Options
562 genes analyzed for SNVs and hotspot mutations (+39 genes compared to TSO500)
Microsatellite instability (MSI) detection across ~50 sites
Copy number variation (CNV) analysis for 57 clinically relevant genes
Selected fusions and tumor mutational burden (TMB) scoring for complete tumor profiling
Add custom biomarkers to differentiate your lab’s testing capabilities
Adaptable for specific clinical or research needs
End-to-End Twist NGS Workflow Compatibility:
Library preparations: EF2.0, cfDNA
Hybridization solutions with options for software analytics
Streamlined workflow for enhanced lab efficiency
Now available in Australia and New Zealand through Decode Science.
Example sequencing QC metrics averaged across data down sampled to 2000x raw coverage (32M 2×150 reads). 4.5 Gb of Data is enough for VAF detections ranging ~2%. Data available upon request.
| Panel target size | 2.4 Mb |
| Example input | 50 ng |
| Mean Target Coverage | 515x |
| On-Target Rate | 77% |
| Fold-80 Base Penalty | 1.32 |
| Duplication Rate | 20% |
| Target bases covered >100x | 99.5% |
TSO-500 : Content is locked at 523 genes in 2025 and beyond
Twist CGP : Offers an updated CPG panel of 562 genes with Twist dsDNA probes
TSO-500 : Not Possible
Twist CGP : Can easily modify content to add genomic features or new biomarkers
TSO-500 : Product is locked into Illumina Platform Ecosystem
Twist CGP : Twist can enable Illumina short-read platforms and non-Illumina platforms (Ultima, Element, etc.)
TSO-500 : Requires an overnight capture + 2nd Hybridization Capture
Twist CGP : Single overnight hybridization capture (Option Trinity on Element)
TSO-500 : High cost per sample for IVD kit pricing
Twist CGP : Can offer competitive pricing and modular kit options.
TSO-500 : Purchase is an all inclusive kit, no option for purchasing components
Twist CGP : Twist can sell modules, or custom configurations through OEM services
Simply add your details below and get quick access to the brochure.
